Oyibo Wellington A, Fagbenro-Beyioku A F
Department of Microbiology, Immunology and Parasitology, Faculty of Medicine, Addis Abbaba University, Addis Ababa, Ethiopia.
Int J Infect Dis. 2003 Jun;7(2):156-9. doi: 10.1016/s1201-9712(03)90013-0.
This study aims to document and underscore the need to monitor adverse reactions following repeated ivermectin treatment under the current dispensation of the implementation of the Community-directed Treatment with Ivermectin (CDTI) Program. As communities are empowered to distribute ivermectin, monitoring of adverse reactions by health care professionals is important in achieving the onchocerciasis control objectives through mass ivermectin therapy.
Eight hundred and ninety subjects from 204 randomly selected households (based on cluster of households) were interviewed using structured questionnaires and in-depth interviews. Responses concerning the adverse effects of ivermectin at the first and sixth rounds were obtained using self-report and treatment records.
Of the 890 individuals, 40.67% presented with adverse reactions at the first round of treatment (TX(1)). This was reduced to 15.06% at the sixth (TX(6)) round of treatment. Pains in joints were more frequently reported at TX(1) and TX(6), 22.7% and 8.5%, respectively.
The relatively mild adverse reaction rates observed at TX(1) did not affect future participation in community treatment with ivermectin, due to adequate community mobilization with health education messages. The current CDTI program has a good chance of achieving the onchocerciasis control program's objectives in Shao, Kwara State, Nigeria.
本研究旨在记录并强调在当前伊维菌素社区定向治疗(CDTI)项目实施过程中,监测重复使用伊维菌素治疗后不良反应的必要性。随着社区被授权分发伊维菌素,医疗保健专业人员对不良反应的监测对于通过大规模伊维菌素治疗实现盘尾丝虫病控制目标至关重要。
使用结构化问卷和深入访谈,对来自204个随机选择家庭(基于家庭群组)的890名受试者进行了访谈。通过自我报告和治疗记录获取了关于伊维菌素在第一轮和第六轮治疗时不良反应的回答。
在890名个体中,40.67%在第一轮治疗(TX(1))时出现不良反应。在第六轮治疗(TX(6))时,这一比例降至15.06%。关节疼痛在TX(1)和TX(6)时报告得更为频繁,分别为22.7%和8.5%。
由于通过健康教育信息进行了充分的社区动员,TX(1)时观察到的相对较轻的不良反应率并未影响未来参与伊维菌素社区治疗。当前的CDTI项目很有可能在尼日利亚夸拉州绍实现盘尾丝虫病控制项目的目标。